These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

297 related articles for article (PubMed ID: 21966435)

  • 21. Dual phosphoinositide 3-kinase/mammalian target of rapamycin inhibitor is an effective radiosensitizer for colorectal cancer.
    Chen YH; Wei MF; Wang CW; Lee HW; Pan SL; Gao M; Kuo SH; Cheng AL; Teng CM
    Cancer Lett; 2015 Feb; 357(2):582-90. PubMed ID: 25497009
    [TBL] [Abstract][Full Text] [Related]  

  • 22. NVP-BEZ235 inhibits thyroid cancer growth by p53- dependent/independent p21 upregulation.
    Ruan B; Liu W; Chen P; Cui R; Li Y; Ji M; Hou P; Yang Q
    Int J Biol Sci; 2020; 16(4):682-693. PubMed ID: 32025215
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Combine MEK inhibition with PI3K/mTOR inhibition exert inhibitory tumor growth effect on KRAS and PIK3CA mutation CRC xenografts due to reduced expression of VEGF and matrix metallopeptidase-9.
    E J; Xing J; Gong H; He J; Zhang W
    Tumour Biol; 2015 Feb; 36(2):1091-7. PubMed ID: 25326806
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Efficacy of the dual PI3K and mTOR inhibitor NVP-BEZ235 in combination with imatinib mesylate against chronic myelogenous leukemia cell lines.
    Xin P; Li C; Zheng Y; Peng Q; Xiao H; Huang Y; Zhu X
    Drug Des Devel Ther; 2017; 11():1115-1126. PubMed ID: 28435223
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Inhibition of Autophagy Increases Proliferation Inhibition and Apoptosis Induced by the PI3K/mTOR Inhibitor NVP-BEZ235 in Breast Cancer Cells.
    Ji Y; Di W; Yang Q; Lu Z; Cai W; Wu J
    Clin Lab; 2015; 61(8):1043-51. PubMed ID: 26427150
    [TBL] [Abstract][Full Text] [Related]  

  • 26. The dual PI3K/mTOR inhibitor NVP-BEZ235 enhances nab-paclitaxel antitumor response in experimental gastric cancer.
    Zhang CΗ; Awasthi N; Schwarz MA; Schwarz RE
    Int J Oncol; 2013 Nov; 43(5):1627-35. PubMed ID: 24042258
    [TBL] [Abstract][Full Text] [Related]  

  • 27. NVP-BEZ235 or JAKi Treatment leads to decreased survival of examined GBM and BBC cells.
    Vazquez N; Lopez A; Cuello V; Persans M; Schuenzel E; Innis-Whitehouse W; Keniry M
    Cancer Treat Res Commun; 2021; 27():100340. PubMed ID: 33636591
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Identification and characterization of NVP-BEZ235, a new orally available dual phosphatidylinositol 3-kinase/mammalian target of rapamycin inhibitor with potent in vivo antitumor activity.
    Maira SM; Stauffer F; Brueggen J; Furet P; Schnell C; Fritsch C; Brachmann S; Chène P; De Pover A; Schoemaker K; Fabbro D; Gabriel D; Simonen M; Murphy L; Finan P; Sellers W; García-Echeverría C
    Mol Cancer Ther; 2008 Jul; 7(7):1851-63. PubMed ID: 18606717
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Dual blockade of PI3K/AKT/mTOR (NVP-BEZ235) and Ras/Raf/MEK (AZD6244) pathways synergistically inhibit growth of primary endometrioid endometrial carcinoma cultures, whereas NVP-BEZ235 reduces tumor growth in the corresponding xenograft models.
    Schrauwen S; Depreeuw J; Coenegrachts L; Hermans E; Lambrechts D; Amant F
    Gynecol Oncol; 2015 Jul; 138(1):165-73. PubMed ID: 25933683
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Utility of a PI3K/mTOR inhibitor (NVP-BEZ235) for thyroid cancer therapy.
    Lin SF; Huang YY; Lin JD; Chou TC; Hsueh C; Wong RJ
    PLoS One; 2012; 7(10):e46726. PubMed ID: 23077520
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Dual inhibition of phosphatidylinositol 3'-kinase and mammalian target of rapamycin using NVP-BEZ235 as a novel therapeutic approach for mucinous adenocarcinoma of the ovary.
    Kudoh A; Oishi T; Itamochi H; Sato S; Naniwa J; Sato S; Shimada M; Kigawa J; Harada T
    Int J Gynecol Cancer; 2014 Mar; 24(3):444-53. PubMed ID: 24552895
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Activity of the novel dual phosphatidylinositol 3-kinase/mammalian target of rapamycin inhibitor NVP-BEZ235 against T-cell acute lymphoblastic leukemia.
    Chiarini F; Grimaldi C; Ricci F; Tazzari PL; Evangelisti C; Ognibene A; Battistelli M; Falcieri E; Melchionda F; Pession A; Pagliaro P; McCubrey JA; Martelli AM
    Cancer Res; 2010 Oct; 70(20):8097-107. PubMed ID: 20876803
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Concomitant BRAF and PI3K/mTOR blockade is required for effective treatment of BRAF(V600E) colorectal cancer.
    Coffee EM; Faber AC; Roper J; Sinnamon MJ; Goel G; Keung L; Wang WV; Vecchione L; de Vriendt V; Weinstein BJ; Bronson RT; Tejpar S; Xavier RJ; Engelman JA; Martin ES; Hung KE
    Clin Cancer Res; 2013 May; 19(10):2688-98. PubMed ID: 23549875
    [TBL] [Abstract][Full Text] [Related]  

  • 34. NVP-BEZ235 and NVP-BGT226, dual phosphatidylinositol 3-kinase/mammalian target of rapamycin inhibitors, enhance tumor and endothelial cell radiosensitivity.
    Fokas E; Yoshimura M; Prevo R; Higgins G; Hackl W; Maira SM; Bernhard EJ; McKenna WG; Muschel RJ
    Radiat Oncol; 2012 Mar; 7():48. PubMed ID: 22452803
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Inhibition of autophagy as a strategy to augment radiosensitization by the dual phosphatidylinositol 3-kinase/mammalian target of rapamycin inhibitor NVP-BEZ235.
    Cerniglia GJ; Karar J; Tyagi S; Christofidou-Solomidou M; Rengan R; Koumenis C; Maity A
    Mol Pharmacol; 2012 Dec; 82(6):1230-40. PubMed ID: 22989521
    [TBL] [Abstract][Full Text] [Related]  

  • 36. The PI3K/mTOR dual inhibitor NVP-BEZ235 reduces the growth of ovarian clear cell carcinoma.
    Oishi T; Itamochi H; Kudoh A; Nonaka M; Kato M; Nishimura M; Oumi N; Sato S; Naniwa J; Sato S; Shimada M; Kigawa J; Harada T
    Oncol Rep; 2014 Aug; 32(2):553-8. PubMed ID: 24927217
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Simultaneous perturbation of the MAPK and the PI3K/mTOR pathways does not lead to increased radiosensitization.
    Kuger S; Flentje M; Djuzenova CS
    Radiat Oncol; 2015 Oct; 10():214. PubMed ID: 26498922
    [TBL] [Abstract][Full Text] [Related]  

  • 38. The dual PI3K/mTOR inhibitor NVP-BEZ235 is a potent inhibitor of ATM- and DNA-PKCs-mediated DNA damage responses.
    Mukherjee B; Tomimatsu N; Amancherla K; Camacho CV; Pichamoorthy N; Burma S
    Neoplasia; 2012 Jan; 14(1):34-43. PubMed ID: 22355272
    [TBL] [Abstract][Full Text] [Related]  

  • 39. The efficacy of the novel dual PI3-kinase/mTOR inhibitor NVP-BEZ235 compared with rapamycin in renal cell carcinoma.
    Cho DC; Cohen MB; Panka DJ; Collins M; Ghebremichael M; Atkins MB; Signoretti S; Mier JW
    Clin Cancer Res; 2010 Jul; 16(14):3628-38. PubMed ID: 20606035
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Dual PI3K/mTOR inhibitor NVP-BEZ235 sensitizes docetaxel in castration resistant prostate cancer.
    Yasumizu Y; Miyajima A; Kosaka T; Miyazaki Y; Kikuchi E; Oya M
    J Urol; 2014 Jan; 191(1):227-34. PubMed ID: 23954373
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 15.